These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 36705240)

  • 1. Molecular Targets for Chalcones in Antileishmanial Drug Discovery.
    de Santiago-Silva KM; da Silva Gomes GF; Perez CC; da Silva Lima CH; de Lima Ferreira Bispo M
    Mini Rev Med Chem; 2023; 23(14):1414-1434. PubMed ID: 36705240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The chemotherapeutic potential of chalcones against leishmaniases: a review.
    Tajuddeen N; Isah MB; Suleiman MA; van Heerden FR; Ibrahim MA
    Int J Antimicrob Agents; 2018 Mar; 51(3):311-318. PubMed ID: 28668673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Computer-aided discovery of two novel chalcone-like compounds active and selective against Leishmania infantum.
    Gomes MN; Alcântara LM; Neves BJ; Melo-Filho CC; Freitas-Junior LH; Moraes CB; Ma R; Franzblau SG; Muratov E; Andrade CH
    Bioorg Med Chem Lett; 2017 Jun; 27(11):2459-2464. PubMed ID: 28434763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The 2',4'-dihydroxychalcone could be explored to develop new inhibitors against the glycerol-3-phosphate dehydrogenase from Leishmania species.
    Passalacqua TG; Torres FA; Nogueira CT; de Almeida L; Del Cistia ML; dos Santos MB; Dutra LA; Bolzani VS; Regasini LO; Graminha MA; Marchetto R; Zottis A
    Bioorg Med Chem Lett; 2015 Sep; 25(17):3564-8. PubMed ID: 26169126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comprehensive review of chalcone derivatives as antileishmanial agents.
    de Mello MVP; Abrahim-Vieira BA; Domingos TFS; de Jesus JB; de Sousa ACC; Rodrigues CR; Souza AMT
    Eur J Med Chem; 2018 Apr; 150():920-929. PubMed ID: 29602038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Promising Molecular Targets Related to Polyamine Biosynthesis in Drug Discovery against Leishmaniasis.
    Santiago-Silva KM; Camargo PG; Bispo MLF
    Med Chem; 2022; 19(1):2-9. PubMed ID: 35838221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of chalcone-based antileishmanial agents targeting trypanothione reductase.
    Ortalli M; Ilari A; Colotti G; De Ionna I; Battista T; Bisi A; Gobbi S; Rampa A; Di Martino RMC; Gentilomi GA; Varani S; Belluti F
    Eur J Med Chem; 2018 May; 152():527-541. PubMed ID: 29758517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chalcones identify cTXNPx as a potential antileishmanial drug target.
    Escrivani DO; Charlton RL; Caruso MB; Burle-Caldas GA; Borsodi MPG; Zingali RB; Arruda-Costa N; Palmeira-Mello MV; de Jesus JB; Souza AMT; Abrahim-Vieira B; Freitag-Pohl S; Pohl E; Denny PW; Rossi-Bergmann B; Steel PG
    PLoS Negl Trop Dis; 2021 Nov; 15(11):e0009951. PubMed ID: 34780470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting chalcone binding sites in living Leishmania using a reversible fluorogenic benzochalcone probe.
    Batista AS; Oliveira SDS; Pomel S; Commere PH; Mazan V; Lee M; Loiseau PM; Rossi-Bergmann B; Prina E; Duval R
    Biomed Pharmacother; 2022 May; 149():112784. PubMed ID: 35299122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The antileishmanial activity of novel oxygenated chalcones and their mechanism of action.
    Zhai L; Chen M; Blom J; Theander TG; Christensen SB; Kharazmi A
    J Antimicrob Chemother; 1999 Jun; 43(6):793-803. PubMed ID: 10404318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of natural anti-parasitic guided development of synthetic drugs for leishmaniasis.
    Pal R; Teli G; Akhtar MJ; Matada GSP
    Eur J Med Chem; 2023 Oct; 258():115609. PubMed ID: 37421889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Broad Spectrum and Safety of Oral Treatment with a Promising Nitrosylated Chalcone in Murine Leishmaniasis.
    Sousa-Batista AJ; Escrivani-Oliveira D; Falcão CAB; Philipon CIMDS; Rossi-Bergmann B
    Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30012761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Compounds with potentialities as novel chemotherapeutic agents in leishmaniasis at preclinical level.
    González-Matos M; Aguado ME; Izquierdo M; Monzote L; González-Bacerio J
    Exp Parasitol; 2024 May; 260():108747. PubMed ID: 38518969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and evaluation of hybrid sulfonamide-chalcones with potential antileishmanial activity.
    de Oliveira NS; de Souza LG; de Almeida VM; Barreto ARR; Carvalho-Gondim F; Schaeffer E; Santos-Filho OA; Rossi-Bergmann B; da Silva AJM
    Arch Pharm (Weinheim); 2024 Mar; 357(3):e2300440. PubMed ID: 38048546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy of leishmaniasis part-VIII: synthesis and bioevaluation of novel chalcones.
    Suryawanshi SN; Chandra N; Kumar P; Porwal J; Gupta S
    Eur J Med Chem; 2008 Nov; 43(11):2473-8. PubMed ID: 18243420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Some Scaffolds as Anti-leishmanial Agents: A Review.
    Mahender T; Pankaj W; Kumar SP; Ankur V; Kumar SS
    Mini Rev Med Chem; 2022; 22(5):743-757. PubMed ID: 34517799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virtual and experimental screening of phenylfuranchalcones as potential anti-Leishmania candidates.
    Ochoa R; García E; Robledo SM; Cardona G W
    J Mol Graph Model; 2019 Sep; 91():164-171. PubMed ID: 31252366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Promising therapeutic targets for antileishmanial drugs.
    Werbovetz KA
    Expert Opin Ther Targets; 2002 Aug; 6(4):407-22. PubMed ID: 12223057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting pteridine reductase 1 and dihydrofolate reductase: the old is a new trend for leishmaniasis drug discovery.
    das Neves GM; Kagami LP; Gonçalves IL; Eifler-Lima VL
    Future Med Chem; 2019 Aug; 11(16):2107-2130. PubMed ID: 31370699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unveiling the Targets Involved in the Quest of Antileishmanial Leads Using In silico Methods.
    Boniface PK; Sano CM; Elizabeth FI
    Curr Drug Targets; 2020; 21(7):681-712. PubMed ID: 32003668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.